Abraham Varghese

881 total citations
35 papers, 521 citations indexed

About

Abraham Varghese is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Abraham Varghese has authored 35 papers receiving a total of 521 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Genetics, 22 papers in Pathology and Forensic Medicine and 14 papers in Immunology. Recurrent topics in Abraham Varghese's work include Chronic Lymphocytic Leukemia Research (26 papers), Lymphoma Diagnosis and Treatment (22 papers) and Immunodeficiency and Autoimmune Disorders (10 papers). Abraham Varghese is often cited by papers focused on Chronic Lymphocytic Leukemia Research (26 papers), Lymphoma Diagnosis and Treatment (22 papers) and Immunodeficiency and Autoimmune Disorders (10 papers). Abraham Varghese collaborates with scholars based in United Kingdom, India and Nigeria. Abraham Varghese's co-authors include Andy C. Rawstron, Peter Hillmen, Paul Moreton, Marwan Kwok, Darren Newton, Paul Evans, Sheila J.M. O’Connor, Roger G. Owen, Christopher Pocock and Andrew R. Pettitt and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Abraham Varghese

31 papers receiving 512 citations

Peers

Abraham Varghese
Wendy G. Nieto Spain
Amy Goodrich United States
Claes Karlsson Sweden
Gilad Itchaki Israel
Viktoria Hjalmar Sweden
Saad M. B. Rassam United Kingdom
J L Binet France
Carol Burian United States
Bhumika J. Patel United States
Carmen D. Schweighofer Germany
Wendy G. Nieto Spain
Abraham Varghese
Citations per year, relative to Abraham Varghese Abraham Varghese (= 1×) peers Wendy G. Nieto

Countries citing papers authored by Abraham Varghese

Since Specialization
Citations

This map shows the geographic impact of Abraham Varghese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abraham Varghese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abraham Varghese more than expected).

Fields of papers citing papers by Abraham Varghese

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abraham Varghese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abraham Varghese. The network helps show where Abraham Varghese may publish in the future.

Co-authorship network of co-authors of Abraham Varghese

This figure shows the co-authorship network connecting the top 25 collaborators of Abraham Varghese. A scholar is included among the top collaborators of Abraham Varghese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abraham Varghese. Abraham Varghese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Varghese, Abraham & Talha Munir. (2024). SOHO State of the Art Updates and Next Questions | Impact of Biologic Markers on Outcomes With Novel Therapy in Chronic Lymphocytic Leukaemia. Clinical Lymphoma Myeloma & Leukemia. 25(6). 381–394.
4.
5.
Kelly, Richard, Matthew T. Holt, Jennifer Vidler, et al.. (2023). Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria. Blood. 143(12). 1157–1166. 21 indexed citations
6.
Richards, Stephen J., Louise Arnold, Abraham Varghese, et al.. (2023). Paroxysmal Nocturnal Haemoglobinuria (PNH) Arising from Non-Canonical Mutations. Blood. 142(Supplement 1). 4097–4097.
7.
Varghese, Abraham, et al.. (2021). Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective. SHILAP Revista de lepidopterología. 2(3). 628–634. 1 indexed citations
8.
Chiattone, Carlos, et al.. (2021). Management of Chronic Lymphocytic Leukemia in Less-Resourced Countries. The Cancer Journal. 27(4). 314–319. 2 indexed citations
9.
Yang, Shenmiao, et al.. (2020). Ethnic and geographic diversity of chronic lymphocytic leukaemia. Leukemia. 35(2). 433–439. 27 indexed citations
10.
11.
Howard, Dena, Talha Munir, Lucy McParland, et al.. (2017). Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. Leukemia. 31(11). 2416–2425. 21 indexed citations
12.
Munir, Talha, Dena Howard, Lucy McParland, et al.. (2017). Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. Leukemia. 31(10). 2085–2093. 20 indexed citations
13.
Kwok, Marwan, Andy C. Rawstron, Abraham Varghese, et al.. (2016). Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 128(24). 2770–2773. 95 indexed citations
14.
Rawstron, Andy C., Dena Howard, Lucy McParland, et al.. (2016). Compartment Effect on the Prognostic Significance of MRD Detection in CLL: Impact of Treatment Type and Duration of Follow-up. Blood. 128(22). 3226–3226. 8 indexed citations
15.
Parrish, Christopher, Gina B. Scott, G Migneco, et al.. (2015). Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia. Leukemia. 29(9). 1799–1810. 32 indexed citations
16.
17.
Owen, Roger G., A. G. Bynoe, Abraham Varghese, Ruth M. de Tute, & Andy C. Rawstron. (2011). Heterogeneity of Histological Transformation Events in Waldenström's Macroglobulinemia (WM) and Related Disorders. Clinical Lymphoma Myeloma & Leukemia. 11(1). 176–179. 19 indexed citations
18.
Hillmen, Peter, D. Cohen, Kim Cocks, et al.. (2011). A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. British Journal of Haematology. 152(5). 570–578. 32 indexed citations
19.
Varghese, Abraham, Andy C. Rawstron, & Peter Hillmen. (2010). Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia: Should This Be the Goal of Treatment?. Current Hematologic Malignancy Reports. 5(1). 35–44. 15 indexed citations
20.
Varghese, Abraham, Andy C. Rawstron, A. John Ashcroft, Paul Moreton, & Roger G. Owen. (2009). Assessment of Bone Marrow Response in Waldenström's Macroglobulinemia. Clinical Lymphoma & Myeloma. 9(1). 53–55. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wendy G. Nieto Breakdown of academic impact, for papers by Amy Goodrich Breakdown of academic impact, for papers by Claes Karlsson Breakdown of academic impact, for papers by Gilad Itchaki Breakdown of academic impact, for papers by Viktoria Hjalmar Breakdown of academic impact, for papers by Saad M. B. Rassam Breakdown of academic impact, for papers by J L Binet Breakdown of academic impact, for papers by Carol Burian Breakdown of academic impact, for papers by Bhumika J. Patel Breakdown of academic impact, for papers by Carmen D. Schweighofer
Rankless by CCL
2026